investing
Craft Cannabis is the Future & Micro-Cultivators Will Lead the Way
Canada’s legal cannabis industry is flooded with products that prioritize profits over quality. While many consumers are price-sensitive, Deloitte Canada found that 86% of Millennial and Gen Z consumers are willing to buy premium products. These trends mirror many other industries where premium products are beating out generic competitors. Maven Brands Inc. (CSE: MJ) […]
LONDON–(BUSINESS WIRE)–Óskare Capital is proud to announce the launch of the first ever SEIS and EIS fund targeting the Medical and Pharmaceutical Cannabis sector. Óskare Capital UK will advise the Fund which is managed by Sapphire Capital Partners LLP. The MEDCAN Fund is the first fund of its kind and will invest in both […]
How to Capitalize on Germany’s Move to Legalize Cannabis
Germany’s incoming governing parties recently announced a formal agreement to legalize adult-use cannabis when they take power. While personal possession has already been decriminalized, the new proposal seeks to establish a regulated market for adult-use cannabis. The move could create an industry like those in Canada and some U.S. states. While the legislation won’t be […]
While Psychedelics Wait, Ketamine Revenues Roll On
The nature of the psychedelic market today means that public company investors are making largely speculative investments. Though there are plenty of studies demonstrating the efficacy of substances ranging from LSD to psilocybin to MDMA, the fact remains they are Schedule 1 controlled substances and have not been approved for therapeutic use. Companies seeking such […]
CALGARY, AB, Nov. 18, 2021 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce its third quarter financial results for the three month period ending September 30, 2021. “Decibel’s continued growth is a testament to our consumer focused approach, the strength of our brands, and our dedication […]
Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets
Vancouver, British Columbia–(Newsfile Corp. – November 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that its common stock ticker will change from “GTSIF” to “LOBEF” and will commence trading under the symbol “LOBEF” in US markets at the opening of the market on November 15, 2021 […]
WestCann: A Unique Business Model with Plenty of Catalysts Ahead
The legal cannabis industry has grown from humble beginnings in the early 2000s into a multi-billion dollar global industry. In addition to THC-containing products capturing market share from the black market, CBD and other cannabinoids have exploded onto the health and wellness scene as researchers continue to uncover potential benefits. Of course, a license to […]
Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of […]
Luff Announces Final Closing of Equity Financing
November 1, 2021 – TheNewswire – Vancouver, B.C. – Luff Enterprises Ltd., (CNSX:LUFF.CN) (“LUFF” or the “Company”) is pleased to announce it has completed its previously announced non-brokered private placement issuing 27,656,002 units of the Company at a price of $0.021 per Unit for aggregate proceeds of $580,776 (the “Private Placement”). Each Unit consists of one common share of […]
Curaleaf Completes Acquisition of Los Sueños
Expands Colorado Outdoor Cultivation Capacity with 66 acres in 2nd Largest U.S. Cannabis Market Acquisition Completes Curaleaf’s Vertical Integration and Bolsters State’s Biomass Production WAKEFIELD, Mass., Oct. 4, 2021 /CNW/ — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, has successfully completed the previously announced acquisition of Los Sueños […]
This marks Avicanna’s first commercial exports of proprietary genetics in the form of feminized seeds into the Peruvian and the Argentine medical cannabis markets. Avicanna worked closely with the Colombian and Argentine ministries of agriculture to establish the phyto-sanitary requirements to allow for continuous supply to the emerging Argentine medical cannabis industry with standardized and […]
Matica Subsidiary West Island Introduces New Brand to the B.C. Non-Medical Cannabis Market
Toronto, Ontario–(Newsfile Corp. – August 18, 2021) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that the Company’s subsidiary, RoyalMax Biotechnology Canada Inc. doing business as West Island Culture (“West Island”) is launching the CITOYEN™ brand of cannabis in British Columbia. West Island is also the maker […]
COOKIES AND TERRASCEND Partner To Bring Top-Shelf Genetics To The Garden State
Licensing Agreement with TerrAscend will provide New Jersey with access to Cookies branded products Additionally, TerrAscend will debut “Cookies Corners” in all three Apothecarium dispensaries in New Jersey August 19, 2021 07:43 AM Eastern Daylight Time BOONTON, N.J.–(BUSINESS WIRE)–International cannabis brand Cookies announced today licensing agreements with TerrAscend NJ LLC, a subsidiary of TerrAscend Corp. (CSE: TER, […]
Grown Rogue and Pure Extracts Form Joint Venture to Expand Product Offering in Michigan
MEDFORD, Ore. & VANCOUVER, British Columbia–(BUSINESS WIRE)–Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE:GRIN) (OTC:GRUSF), a multi-state operating (MSO) cannabis company with operations and assets in Oregon and Michigan, today announced the signing of a Definitive Agreement for a joint venture between its Michigan partner, Golden Harvests, LLC (“Golden”) and Pure Extracts Technologies […]
Ketamine One’s KGK Science Acquisition Provides Numerous Benefits
KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, […]
Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure
– New innovative “Amalgamated Trichomes Coral Structure” withstands shear forces applied by the liquid medium – New structure acts as a protective shield enabling stable trichome development throughout the growth process – Historic scientific milestone validates BioHarvest’s path to commercialization of Cannabis in H1 2022 CSE:BHSC – FSE:8MV – OTC: CNVCF OFSE:8MV BioHarvest Sciences Inc.’s […]
Big Data, Acquisitions Point the Way for Plant-Based Medicines
How do you know if plant-based medicines are hitting the mainstream? One indicator might be when tobacco giant Philip Morris International makes a $1.45 billion offer to acquire Vectura, a firm focused on inhaled medicine formulations and devices. The move is part of PMI’s pivot away from harmful tobacco products and toward “respiratory drug delivery […]
The psychedelic renaissance has taken the research community by storm, but psilocybin, DMT, MDMA, and other therapies remain in development. Ketamine is the only widely available psychedelic therapy that the FDA approves to treat depression and suicidal ideations. As a result, investors may want to start there for near-term opportunities. Let’s take a look at […]
Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to $30+ Billion RA Market
Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it. Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical […]
Premium Brand Leader Upping the Ante for Cannabis 2.0 Products
Canada made whole new classes of cannabis products legal for recreational use in October 2019. Hailed as Cannabis 2.0, the introduction of products such as vapes, oils, and edibles was anticipated to offer a new high-growth category in the already booming legal cannabis industry. Due to a variety of factors, including an uneven regulatory rollout […]
Optimi Health Joins First Psychedelic Exchange Traded Fund
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF began trading on the Neo Exchange as of […]
Decibel Appoints Paul Wilson as CEO
CALGARY, AB, June 22, 2021 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce the appointment of Paul Wilson as its Chief Executive Officer, effective Wednesday, June 23rd. Emphasizing the Company’s objective for brand growth, Mr. Wilson brings CEO and President level experience from some of Canada’s top consumer brands […]
Dispensaries Can Boost Cannabis Sales with Unique Topical Products
As the legal cannabis industry matures and expands, the goal of many companies is (and should be) to reach people who might not historically be cannabis consumers. According to a 2020 Gallup poll, about 12% of US adults say they smoke marijuana. This percentage has remained fairly steady over the past several years, even […]
Medxtractor Looks to Transform Mobile Health with Machine-Learning
Machine-Learning (“ML”) (sometimes referred to as artificial intelligence or “AI”) has experienced a renaissance over the past five years thanks to a combination of big data, fast processors, and new algorithms. ML is all around us; from stock trading to autonomous vehicles, ML is already transforming a wide range of industries by finding patterns in […]
Cybin Looks to Develop the Next Blockbuster Drugs
The pharmaceutical industry has struggled for years to develop effective psychiatric and neurological treatments. For example, many antidepressants and antipsychotics show only marginal efficacy in reducing symptoms compared to placebos over the short-term. The long-term use of many psychiatric drugs is also associated with adverse side-effects. Psychedelics are an exciting development in neuropsychiatry because of […]
Why Are Analysts So Bullish on Cybin?
The global psychedelics market is projected to grow from $4.75 billion to $10.75 billion by 2027, according to Research and Markets, representing a strong 12.36% compound annual growth rate. With more than 40 public companies in the psychedelics sector and an exchange-traded fund, there is no shortage of opportunities for investors interested in the space. […]
Revive Takes a Step Closer to Launching New Psychedelic Delivery Mechanism
Mental illness is the leading cause of disability in developed countries. In fact, half of Americans will experience mental illness in their lifetime and $350 billion is spent each year on treating depression in the U.S. and Europe alone. Psychedelics have emerged as a breakthrough treatment for many mental health disorders with fast-acting results, […]
Psychedelics Then & Now: From Ancient Times to the Psychedelic Renaissance
Psychedelics have become one of the most promising classes of drugs in a generation, as well as an exciting new industry for investors. Despite their resurgence among researchers and investors, psychedelics have been used for thousands of years before they were criminalized in the 1970s in the United States and around the world. Let’s take […]
Ovation Science Takes Topical Cannabis to the Next Level with Its Patented Drug Delivery Technology
Cannabinoids have become some of the most popular health and wellness products in the world. For example, CBD-infused topicals are expected to reach $4.5 billion in sales by 2025, according to Cultivating Wellness, which represents a 540% increase since 2020. At the same time, topicals infused with THC or combinations of CBD and THC are […]
Aufruf an alle Derivate: Der psychedelische Bereich braucht euch
Im Jahr 2020 genehmigte das Center for Drug Evaluation and Research der US-amerikanischen Food and Drug Administration 53 neuartige Arzneimittel, die zweithäufigste Zulassung in einem einzigen Jahr seit 23 Jahren, die nur vom Rekordjahr 2018 mit 59 Zulassungen übertroffen wurde. Von den neuen Arzneimitteln wurden 58 Prozent für seltene Krankheiten zugelassen, bei denen die […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC cannabis formulations including ARLO CBD Beauty and InVibe® MD (“health & wellness” line), and secondly, its unique DermSafe® hand sanitizer; all made with its patented Invisicare® skin delivery technology.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
